Christian Brander

List of Publications by Citations

92 papers	6,800 citations	37 h-index	82 g-index
98 ext. papers	7,542 ext. citations	8 avg, IF	4.77 L-index

#	Paper	IF	Citations
92	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. *Nature Medicine*, **2007**, 13, 46-53	50.5	824
91	Evolution and transmission of stable CTL escape mutations in HIV infection. *Nature*, **2001**, 412, 334-8	50.4	488
90	HLA class I supertypes: a revised and updated classification. *BMC Immunology*, **2008**, 9, 1	3.7	463
89	Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. *Journal of Experimental Medicine*, **2001**, 193, 375-86	16.6	400
88	Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. *Journal of Experimental Medicine*, **2001**, 193, 169-80	16.6	334
87	Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. *Journal of Virology*, **2007**, 81, 12382-93	6.6	274
86	Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. *PLoS Pathogens*, **2012**, 8, e1002529	7.6	270
85	Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. *Journal of Virology*, **2006**, 80, 3122-5	6.6	254
84	Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. *Journal of Experimental Medicine*, **2001**, 193, 181-94	16.6	241
83	Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. *Science*, **2015**, 348, aaa0698	33.3	231
82	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. *Nature Immunology*, **2006**, 7, 173-8	19.1	193
81	Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. *Journal of Virology*, **2004**, 78, 4463-77	6.6	157
80	Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. *Journal of Immunology*, **2006**, 176, 4094-101	5.3	136
79	Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. *PLoS ONE*, **2008**, 3, e1424	3.7	133
78	HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. *PLoS ONE*, **2009**, 4, e6687	3.7	131
77	Efficient generation of human T cells from a tissue-engineered thymic organoid. *Nature Biotechnology*, **2000**, 18, 729-34	44.5	127
76	Definition of the viral targets of protective HIV-1-specific T cell responses. *Journal of Translational Medicine*, **2011**, 9, 208	8.5	124

75	Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. *Journal of Virology*, **2008**, 82, 5594-605	6.6	122
74	Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. *Journal of Immunological Methods*, **2003**, 275, 19-29	2.5	120
73	Extensive HLA class I allele promiscuity among viral CTL epitopes. *European Journal of Immunology*, **2007**, 37, 2419-33	6.1	106
72	Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. *Journal of Immunology*, **2014**, 193, 1988-97	5.3	105
71	CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. *PLoS ONE*, **2012**, 7, e29717	3.7	103
70	High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. *Journal of Virology*, **2011**, 85, 9334-45	6.6	99
69	IL-8 responsiveness defines a subset of CD8 T cells poised to kill. *Blood*, **2004**, 104, 3463-71	2.2	73
68	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. *Journal of Translational Medicine*, **2015**, 13, 60	8.5	60
67	Gradual adaptation of HIV to human host populations: good or bad news?. *Nature Medicine*, **2003**, 9, 1359-62	3.63	60
66	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. *Aids*, **2018**, 32, 2533-2545	3.5	50
65	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1833-42	5.1	47
64	Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. *Journal of Virology*, **2008**, 82, 3147-53	6.6	47
63	Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population. *Journal of Immunology*, **2005**, 175, 4355-62	5.3	46
62	Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. *Journal of Experimental Medicine*, **2010**, 207, 61-75	16.6	43
61	Virological, Immune and Host genetics Markers in the Control of HIV Infection. *Disease Markers*, **2009**, 27, 105-120	3.2	43
60	Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. *PLoS ONE*, **2014**, 9, e86254	3.7	42
59	Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. *Journal of Virology*, **2012**, 86, 12643-54	6.6	42
58	The challenges of host and viral diversity in HIV vaccine design. *Current Opinion in Immunology*, **2006**, 18, 430-7	7.8	41

57	Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells. *Journal of Virology*, **2014**, 88, 12992-3004	6.6	39
56	Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. *PLoS Pathogens*, **2015**, 11, e1004658	7.6	38
55	HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. *PLoS ONE*, **2013**, 8, e60245	3.7	36
54	Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". *Journal of Translational Medicine*, **2005**, 3, 20	8.5	33
53	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). *EClinicalMedicine*, **2019**, 11, 65-80	11.3	30
52	Increased sequence diversity coverage improves detection of HIV-specific T cell responses. *Journal of Immunology*, **2007**, 179, 6638-50	5.3	30
51	Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. *Blood*, **2002**, 100, 698-700	2.2	30
50	Lytic and latent antigens of the human gammaherpesviruses Kaposiβ sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes. *Journal of Virology*, **2007**, 81, 4904-8	6.6	29
49	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). *Frontiers in Immunology*, **2020**, 11, 823	8.4	28
48	Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. *Aids*, **2008**, 22, 447-56	3.5	27
47	Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). *Aids*, **2017**, 31, 321-332	3.5	27
46	Increased expression of SAMHD1 in a subset of HIV-1 elite controllers. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 3057-60	5.1	25
45	Discrimination of human CD4 T cell clones based on their reactivity with antigen-presenting T cells. *European Journal of Immunology*, **1992**, 22, 2295-302	6.1	25
44	Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. *PLoS ONE*, **2017**, 12, e0176418	3.7	25
43	Virological, immune and host genetics markers in the control of HIV infection. *Disease Markers*, **2009**, 27, 105-20	3.2	25
42	A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 9981-9990	11.5	23
41	Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide. *European Journal of Immunology*, **1993**, 23, 3217-23	6.1	22
40	Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences. *PLoS ONE*, **2011**, 6, e17969	3.7	18

39	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. *Trials*, **2019**, 20, 361	2.8	17
38	Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1. *Journal of Virology*, **2015**, 89, 4015-9	6.6	17
37	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. *PLoS ONE*, **2015**, 10, e0141456	3.7	17
36	Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. *Journal of Virology*, **2019**, 93,	6.6	15
35	Strong sex bias in elite control of paediatric HIV infection. *Aids*, **2019**, 33, 67-75	3.5	14
34	Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. *Frontiers in Immunology*, **2020**, 11, 418	8.4	13
33	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. *Vaccines*, **2019**, 7,	5.3	13
32	HIV T-Cell Vaccines. *Advances in Experimental Medicine and Biology*, **2018**, 1075, 31-51	3.6	12
31	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. *PLoS ONE*, **2017**, 12, e0184929	3.7	12
30	Novel Approaches Towards a Functional Cure of HIV/AIDS. *Drugs*, **2020**, 80, 859-868	12.1	12
29	Zip6 Transporter Is an Essential Component of the Lymphocyte Activation Machinery. *Journal of Immunology*, **2019**, 202, 441-450	5.3	12
28	Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. *Journal of Infectious Diseases*, **2015**, 211, 936-46	7	11
27	Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. *PLoS ONE*, **2014**, 9, e87334	3.7	11
26	Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. *Vaccines*, **2019**, 7,	5.3	7
25	A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. *Microbes and Infection*, **2017**, 19, 69-74	9.3	7
24	In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. *PLoS Pathogens*, **2020**, 16, e1008607	7.6	6
23	HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency. *Frontiers in Microbiology*, **2018**, 9, 1066	5.7	6
22	Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. *Aids*, **2015**, 29, 1309-18	3.5	6

21	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. *Aids*, **2016**, 30, 553-62	3.5	6
20	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 418-428	6.4	5
19	Benzyl-2-Acetamido-2-Deoxy-□d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy. *Frontiers in Immunology*, **2017**, 8, 2010	8.4	5
18	HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-□2/□2. *Immunobiology*, **2013**, 218, 543-7	3.4	5
17	SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development. *Vaccines*, **2020**, 8,	5.3	5
16	T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. *Cytotherapy*, **2015**, 17, 1280-91	4.8	4
15	Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design. *Current Opinion in HIV and AIDS*, **2007**, 2, 183-8	4.2	4
14	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. *PLoS ONE*, **2018**, 13, e0208345	3.7	4
13	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. *Journal of Translational Medicine*, **2013**, 11, 48	8.5	3
12	Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. *PLoS ONE*, **2019**, 14, e0212347	3.7	2
11	FARMS: A New Algorithm for Variable Selection. *BioMed Research International*, **2015**, 2015, 319797	3	2
10	Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Naïve HIV-Infected Individuals. *PLoS ONE*, **2016**, 11, e0147571	3.7	2
9	Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection. *Retrovirology*, **2015**, 12, 80	3.6	1
8	Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients. *European Journal of Immunology*, **2013**, 43, 1545-54	6.1	1
7	TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses. *Journal of Immunology*, **2020**, 205, 3348-3357	5.3	1
6	Considerations for successful therapeutic immunization in HIV cure. *Current Opinion in HIV and AIDS* , **2021**, 16, 257-261	4.2	1
5	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?. *Frontiers in Immunology*, **2020**, 11, 573928	8.4	1
4	Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 1032-1040	5.1	0

3	Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8 T cell antiviral responses. *Cell Reports*, **2021**, 35, 109103	10.6	0
2	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.. *EBioMedicine*, **2022**, 78, 103956	8.8	0
1	Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality. *AIDS Research and Human Retroviruses*, **2014**, 30, A194-A194	1.6	